Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Year: 2019
Type: article
Abstract: Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting. Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report, we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN.
Source: Molecular Cancer Therapeutics
Institutions: Emory University, Winship Cancer Institute, Atlantic Health System, University of Brescia, University of Udine, Hospital Universitario Central de Asturias, University of Helsinki, Helsinki University Hospital, Radboud University Medical Center, Institute of Oncology Ljubljana, Antwerp University Hospital
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1823531124, G2297711425, G9000017109
OpenAlex ID: W2986981633